PARIS and GRENOBLE, FRANCE – October 21^st, 2021 – LXRepair, a pioneer in personalized radiotherapy with functional assays measuring DNA repair to predict treatment response, with a clinical proof-of-concept of radiotoxicity prediction in breast and prostate cancer, and Gustave Roussy, Europe's leading cancer center, announced today the launch of a joint laboratory to improve the personalization of radiotherapy. Read more…

Stéphane Altaba, with extensive experience in biotechnology companies, becomes CEO of LXRepair.
He will lead the commercial launch of Safer Rad-LX®, the first predictive test on toxicity of radiotherapy treatments, and he is expected to raise Series A financing, scheduled for 2021.

Press release EN / FR

Innopsys and LXRepair entered an agreement in the context of  the development of LXRepair diagnostic test RAD-LX™. RAD-LX™ is intended to predict radiotherapy adverse effects in patients receiving radiotherapy. LXRepair clinical proof of concept study is conducted on 300 patients in collaboration with Pr N. Magné from Institut de Cancérologie Lucien Neuwirth and is almost completed.
LXRepair will use InnoScan scanner.
This project is supported by a Bpifrance innovation program.

LXRepair filed a patent application based on the analysis of melanoma samples using its SPOT-LX™ platform to generate DNA Repair profiles from tumors. The patent application outlines a method for stratifying patients, identifying DNA Repair defects and choose the best therapeutic option notably between targeted therapy and immunotherapy. LXRepair will continue its clinical research on melanoma to eventually develop a diagnostic test MELX™.

LXRepair, a leading DNA Damage Response (DDR) company developing innovative stratification tools for cancer, announces the successful recruitment of an expert in Diagnostic Development and Quality Manager, Dr Thierry Maillet who earned a PhD in Molecular Biochemistry and Biophysics from the University of Orléans. Thierry is in charge of the RAD-LX development and certifications.

Thierry has over 25 years of experience in the in vitro diagnostic industry. In particular he worked for 18 years at Stago as Development and Manufacturing manager. Thierry joins LXRepair from the French regulatory authority for health products safety, where he held the position of Certified Inspector during 5 years.

LXREPAIR, a French company specialized in the development of disruptive technologies for DNA repair characterization, announces it has raised €1.1M from KREAXI, CEA-Investment, XPAND INVESTMENT Ltd of the KIS Group, Grenoble Angels, Savoie Mont-Blanc Angels, Gentiane Participation and individual investors.

The funds will be used to complete LXRepair clinical proof of concepts in oncology, to obtain the CE marking of the kits and for international business development.

Glyco-SPOT DNA Repair Assay kit : a ready-to-use kit to quantify enzymatic activities responsible for DNA Repair